Merrem I.V. Related Published Studies
Well-designed clinical trials related to Merrem I.V. (Meropenem)
Evaluation of the efficacy and safety of intravenous ciprofloxacin versus meropenem in the treatment of postoperative infection. [2011.10.19]
Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. [2010.11]
Efficacy of ceftriaxone or meropenem as initial therapies in Whipple's disease. [2010.02]
Microbiological equivalence of serum bacteriostatic and bactericidal activities of the sera from healthy volunteers receiving original meropenem (Meronem) and generic meropenem (Mero). [2010.01]
Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. [2009.07]
Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. [2006.07]
Timing of antibiotic prophylaxis in acute pancreatitis: a controlled randomized study with meropenem. [2006.06]
Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors. [2006.04]
The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. [2005.10]
Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. [2005.09]
Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. [2005.05]
Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. [2005.04]
Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. [2005]
Meropenem +/- granulocyte colony stimulating factor in the treatment of febrile neutropenic patients with cancer: prospective randomized study. [2004.06]
Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. [2004.04]
Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy. [2003.12]
Prophylaxis with meropenem of septic complications in acute pancreatitis: a randomized, controlled trial versus imipenem. [2003.11]
Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection. [2003.09]
Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. [2003.08]
A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections. [2002.12]
[A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections] [2001.09]
Effects of cefepime and meropenem on the gastrointestinal colonization of surgical patients by Candida albicans. [2001.09]
Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. [2001.06]
Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. [2001.06]
Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors. [2001.04]
Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. [2001.02]
[Efficacy of monotherapy by meropenem in ventilator-associated pneumonia] [2001]
Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. [2000.11.01]
Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. [2000.06]
Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients. [2000.05]
Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients. [2000.03]
Cost-effectiveness study of imipenem/cilastatin versus meropenem in intra-abdominal infections. [2000]
Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey. [1999.09]
Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group. [1999.07]
Continuous infusion versus intermittent administration of meropenem in critically ill patients. [1999.04]
Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections. [1999.02]
Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia. [1999]
[Comparative study of meropenem and amikacin/metronidazole combination in the treatment of severe abdominal surgical infections] [1998.11.08]
[Prospective randomized trial of meropenem versus cefotaxime and metronidazole in the treatment of intraabdominal infections] [1998.06.27]
Meropenem versus cefuroxime plus gentamicin for treatment of serious infections in elderly patients. [1998.05]
Meropenem compared with ceftazidime in the empiric treatment of acute severe infections in hospitalized children. Italian Pediatric Meropenem Study Group. [1998.04]
Treatment of obstetric and gynecologic infections with meropenem: comparison with imipenem/cilastatin. [1998.04]
Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. [1998.02]
Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime. [1998.02]
Empiric monotherapy for febrile neutropenia--a randomized study comparing meropenem with ceftazidime. [1998]
[Multicenter open randomized trial of meropenem in comparison to ceftazidime and amikacin used in combination in severe hospital infections] [1998]
Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study. [1997.11]
Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. [1997.11]
Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group. [1997.10]
A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections. [1997.05]
[Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study] [1997.03]
A multicenter study comparing intravenous meropenem with clindamycin plus gentamicin for the treatment of acute gynecologic and obstetric pelvic infections in hospitalized women. [1997.02]
Results of a randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra-abdominal infections. [1997.02]
Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. [1997]
Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients. [1996.11]
Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections. [1996.11]
Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group. [1996.09]
Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. [1996.05]
Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitis. [1996.05]
Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. [1996.01]
[Multicenter comparative study of meropenem vs. imipenem in the intramuscular treatment of hospital infections of the urinary tract] [1995.09]
Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. [1995.09]
Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. [1995.07]
A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group. [1995.07]
Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group. [1995.07]
Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. [1995.07]
Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin. [1995.07]
Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group. [1995.07]
Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. [1995.07]
Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group. [1995.07]
Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. Italian Intramuscular Meropenem Study Group. [1995.07]
A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients. [1995.07]
Comparison of the activity of meropenem with that of other agents in the treatment of intraabdominal, obstetric/gynecologic, and skin and soft tissue. [1995.06]
Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group. [1995.05]
Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. [1995.04]
Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. [1995.01]
Pharmacokinetics of meropenem in patients with intra-abdominal infections. [1994.01]
Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery. [1993.06]
Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion. [1991.12]
The pharmacokinetics of meropenem in volunteers. [1989.09]
Well-designed clinical trials possibly related to Merrem I.V. (Meropenem)
Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter
double-blind, randomized controlled trial. [2013]
A protocol for a multicentre randomised controlled trial of continuous
beta-lactam infusion compared with intermittent beta-lactam dosing in critically
ill patients with severe sepsis: the BLING II study. [2013]
Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter
double-blind, randomized controlled trial. [2013]
Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. [2011.02]
Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital. [2010.08]
[Comparison of micafungin and fosfluconazole as prophylaxis for invasive fungal infection during neutropenia in children undergoing chemotherapy and hematopoietic stem cell transplantation] [2009.12]
Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. [2008.03]
Correlates of clinical failure in ventilator-associated pneumonia: insights from a large, randomized trial. [2008.03]
Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. [2008.01]
Empiric antibiotic therapy for suspected ventilator-associated pneumonia: A systematic review and meta-analysis of randomized trials. [2007.11.13]
[Effectiveness of switch therapy for peritonitis] [2007.08]
Impact of carbapenem administration on systemic endotoxemia in patients with severe sepsis and Gram-negative bacteremia. [2006.10]
Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. [2006.02]
Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. [2005.07]
Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison. [2003.06]
Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. [2003]
Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy. [2002.12]
Impact an anatomical site on bacteriological and clinical outcome in the management of intra-abdominal infections. [1998.05]
Immune response in patients with intra-abdominal infections treated with carbapenems. [1994]
Adjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenems. [1991.12]
|
